Drug Type Bispecific antibody |
Synonyms GR 2202, GR2202 |
Target |
Action antagonists |
Mechanism IL-1R antagonists(Immunoglobulin-like family of IL-1 receptors antagonists) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammatory Bowel Diseases | Preclinical | China | 04 Sep 2024 | |
Psoriasis | Preclinical | China | 04 Sep 2024 |